NanoString Technologies (NASDAQ:NSTG) and DBV TECHNOLOGIE/S (NASDAQ:DBVT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, risk, dividends and profitability.
Analyst Ratings
This is a breakdown of current ratings for NanoString Technologies and DBV TECHNOLOGIE/S, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NanoString Technologies | 0 | 0 | 2 | 0 | 3.00 |
| DBV TECHNOLOGIE/S | 0 | 1 | 5 | 0 | 2.83 |
NanoString Technologies presently has a consensus price target of $31.50, indicating a potential upside of 13.23%. DBV TECHNOLOGIE/S has a consensus price target of $16.60, indicating a potential upside of 55.14%. Given DBV TECHNOLOGIE/S’s higher probable upside, analysts clearly believe DBV TECHNOLOGIE/S is more favorable than NanoString Technologies.
Insider and Institutional Ownership
32.9% of DBV TECHNOLOGIE/S shares are held by institutional investors. 5.1% of NanoString Technologies shares are held by insiders. Comparatively, 15.3% of DBV TECHNOLOGIE/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Volatility & Risk
NanoString Technologies has a beta of 1.16, indicating that its stock price is 16% more volatile than the S&P 500. Comparatively, DBV TECHNOLOGIE/S has a beta of 1.79, indicating that its stock price is 79% more volatile than the S&P 500.
Valuation and Earnings
This table compares NanoString Technologies and DBV TECHNOLOGIE/S’s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NanoString Technologies | $106.73 million | 9.32 | -$77.40 million | ($2.78) | -10.01 |
| DBV TECHNOLOGIE/S | $17.17 million | 56.89 | -$196.14 million | ($3.39) | -3.16 |
NanoString Technologies has higher revenue and earnings than DBV TECHNOLOGIE/S. NanoString Technologies is trading at a lower price-to-earnings ratio than DBV TECHNOLOGIE/S, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares NanoString Technologies and DBV TECHNOLOGIE/S’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NanoString Technologies | -72.30% | -118.32% | -41.75% |
| DBV TECHNOLOGIE/S | N/A | N/A | N/A |
Summary
DBV TECHNOLOGIE/S beats NanoString Technologies on 10 of the 14 factors compared between the two stocks.
NanoString Technologies Company Profile
NanoString Technologies, Inc. provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; and Pan Cancer and 360 gene expression, CAR-T characterization, protein immune profiling, neuropathology and neuro-inflammation gene expression, Mouse-AD, autoimmune disease gene expression, miRNA expression, and other gene expression panels. Further, the company offers nCounter based reagents that allow users to design customized assays; Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and nCounter Dx Analysis System and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics; and Hyb & Seq molecular profiling system to determine and analyze gene sequences within biological samples. It has collaboration with Celgene Corporation; Merck & Co., Inc.; Medivation, Inc.; and Astellas Pharma, Inc, as well as strategic partnership with Bio-Techne Corp. The company was founded in 2003 and is headquartered in Seattle, Washington.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase II clinical trial for the treatment of Immunoglobulin E mediated cow’s milk protein allergy (CMPA) and milk-induced eosinophilic esophagitis; Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordatella pertussis. Its other earlier stage research programs include vaccine for respiratory syncytial virus, as well as treatments for Crohn’s disease, hemophilia A, celiac disease, and type I diabetes. The company has collaboration with Nestlé Health Science to develop MAG1C, an atopy patch test for the diagnosis of CMPA in infants and toddlers. DBV Technologies S.A. was founded in 2002 and is headquartered in Montrouge, France.
Receive News & Ratings for NanoString Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for NanoString Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.
